Citadel Advisors
DMRA

Citadel Advisors’s Damora Therapeutics DMRA Stock Holding History

Citadel Advisors’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.33M Buy
+166,347
New +$4.03M ﹤0.01% 4982
2024
Q3 		– Sell
-5,143
Closed -$61K – 14579
2024
Q2 		$61K Buy
5,143
+1,403
+38% +$22.2K ﹤0.01% 11547
2024
Q1 		$72.9K Buy
3,740
+843
+29% +$15K ﹤0.01% 11765
2023
Q4 		$52.2K Buy
+2,897
New +$44.5K ﹤0.01% 11742
2023
Q3 		– Sell
-89
Closed -$5.64K – 14589
2023
Q2 		$5.64K Sell
89
-105
-54% -$5.72K ﹤0.01% 13483
2023
Q1 		$9.65K Buy
+194
New +$10.2K ﹤0.01% 13579

Other funds holding DMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCP
Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

Citadel Advisors's DMRA Position: Q2 2026 in Review

Citadel Advisors opened a new position in Damora Therapeutics (DMRA) in Q2 2026: 166,347 shares worth $4.33M. The stake represents ﹤0.01% of the portfolio and ranks #4982 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in DMRA as recently as Q2 2024.

Citadel Advisors first reported a position in DMRA in Q1 2023 and has held it in 6 quarters since. 104 funds tracked by Wall St. Rank hold DMRA as of Q2 2026.

  • Citadel Advisors held 166,347 shares of Damora Therapeutics worth $4.33M as of Q2 2026.
  • Damora Therapeutics was a new Citadel Advisors position in Q2 2026.
  • Damora Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #4982 holding.
  • Citadel Advisors first reported a position in Damora Therapeutics in Q1 2023 and has held it in 6 quarters since.
  • 104 funds tracked by Wall St. Rank held Damora Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.